In today’s briefing:
- NIFTY Outlook: Possible Breakout as Options Expiry Moves to Monday
- Ashok Leyland Restructuring: Switch UK Winds Down & Switch India’s Strategic Pivot
- How SEBI’s Expiry Date Proposal Could Halt BSE’s Market Share Erosion?
- Innova Captab’s Jammu Expansion Update
- Kolte Patil: Q3FY25 Performance and Promoter Change Update
NIFTY Outlook: Possible Breakout as Options Expiry Moves to Monday
- The NIFTY Index had rallied quite hard the week before last week, then stalled last week, however its looks like maybe is changing in its trend structure, maybe a breakout…
- However the breakout may have to wait a bit more, as the NIFTY is overbought WEEKLY according to our model: before the uptrend resumes, there will be a pullback.
- Last: as written by AceGama Advisors the WEEKLY options expiry will be moved from Thursday to Monday, starting in April 2025, impacting the market. Read their insight for detailed analysis.
Ashok Leyland Restructuring: Switch UK Winds Down & Switch India’s Strategic Pivot
- Ashok Leyland (AL IN) plans to shut manufacturing at its UK EV subsidiary, Switch Mobility UK, and shift focus to India and UAE plants.
- The UK exit curbs cash burn and earnings drag, while Switch India, driven by rising demand, nears breakeven with 1800+ e-Bus orders and 80%+ e-LCV share.
- This marks a value-accretive pivot, realigning capital to India’s high-growth EV market and improving group-level profitability and return metrics.
How SEBI’s Expiry Date Proposal Could Halt BSE’s Market Share Erosion?
- SEBI’s March 27 proposal suggests standardising expiry dates: Thursdays for Bombay Stock Exchange (BSE IN) and Tuesdays for National Stock Exchange (NSEIN IN) .
- NSE’s previous strategic expiry days aimed at better liquidity, marginalising BSE’s Tuesday expiry, potentially impacting it’s trading volumes.
- Post-Consultation was released, NSE faces a setback, deferring its planned monday expiry shift for Nifty contracts, indirectly protecting BSE from market share erosion.
Innova Captab’s Jammu Expansion Update
- Innova Captab (1605221D IN) has commissioned a new 11-acre manufacturing facility in Jammu, with capacity for 10.7 bn tablets and 562 mn LVP/respules.
- The plant adds new dosage forms and therapy areas (Penicillin, Penum) and enables strategic domestic-export capacity balancing, with potential ROIC >20%.
- This is not just a capacity bump, it positions Innova for premium exports, higher utilization, and long-term revenue scale-up to INR 14–16Bn from Jammu alone.
Kolte Patil: Q3FY25 Performance and Promoter Change Update
- Kolte Patil’s Q3FY25 performance update’s key highlight was acquisition of a 22 acre joint development project with topline potential worth INR 4000cr representing saleable area of 5 Million Square Feet.
- Q3FY25 pre-sales was not as robust as approval of new projects got delayed in Mumbai due to elections. However, Kolte Patil has guided to cover this up in early FY26.
- Even with the delay, Kolte Patil is projecting to close FY25 pre-sales at INR 3000cr+ (vs INR 3500cr guided), which implies that Q4FY25 pre-sales could be INR 850cr+.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
